<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327155</url>
  </required_header>
  <id_info>
    <org_study_id>HEPP1701</org_study_id>
    <nct_id>NCT03327155</nct_id>
  </id_info>
  <brief_title>Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial</brief_title>
  <acronym>PrEPIT-WA</acronym>
  <official_title>Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Government of Western Australia, Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Western Australia AIDS Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite all prevention efforts, many people in Australia continue to be infected with HIV.
      The Seventh National HIV Strategy 2014-2017 in Australia aims to work towards the elimination
      of HIV transmission by the year 2020. This project will evaluate a new additional way to
      lower people's chances of getting HIV. It will provide pre-exposure prophylaxis (PrEP) to
      people who are at high risk for HIV and evaluate what impact this new prevention approach
      will have on HIV in WA at the community level.

      The drug used in PREPIT-WA is called generic TDF/FTC (made by Mylan Laboratories Ltd.). The
      generic TDF/FTC is a single tablet made up of two HIV medications: tenofovir disoproxil
      fumarate and emtricitabine (a combination known as TDF/FTC). TDF and FTC have been widely
      used for many years to treat HIV. When used with other medicines in people who already have
      HIV, TDF/FTC reduces the amount of HIV virus in the blood. TDF/FTC does not cure HIV or AIDS,
      and it is not an HIV vaccine.

      As a treatment for people who already have HIV, TDF/FTC is approved for use in most of the
      world, including Australia. As a medicine for PrEP, to lower chances of HIV in those who are
      not infected, TDF/FTC has been approved in the US, and Truvada速 (which contains TDF/FTC made
      by Gilead Sciences Inc.) was approved for PrEP in Australia in May 2016. At the start of the
      project, the generic TDF/FTC is not approved in Australia for the use as PrEP but it may
      become registered for use and more freely available in Australia in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Australian seventh National HIV strategy (2014-2017) aims to reduce the incidence of HIV
      and to work towards the virtual elimination of HIV transmission in Australia by 2020. This
      extraordinary goal relies on two anti-retroviral therapy (ARV)-related interventions, in
      addition to traditional behavioural prevention. The first of these interventions, HIV
      treatment as prevention targeted at HIV positive people, has been ramped up over the last few
      years, and is approaching maximal levels of population impact. Despite this, new HIV
      diagnoses in Australia have been approximately constant over the last four years. Critical to
      the new strategy's success is the population-based, targeted roll-out of HIV PrEP. PrEP
      involves taking one pill daily of co-formulated tenofovir disoproxil fumarate
      (TDF)/emtricitabine (FTC). TDF/FTC has been extensively used in millions of people with HIV
      for more than 15 years.

      This large-scale study aims for the rapid roll-out of TDF/FTC to individuals at high risk of
      HIV, who will comprise mostly gay and bisexual men (GBM) but will also include small numbers
      of heterosexuals, people who inject drugs, and transgender men and women. The drug will be
      used according to existing Australasian Society for HIV, Viral Hepatitis and Sexual Health
      (ASHM) HIV PrEP Clinical Guidelines.

      By rapidly rolling out this new intervention as rapidly as feasible, and following
      participants for up to two years on treatments, we expect a reduction in new HIV diagnoses in
      WA due to decreased infection in the on-treatment cohort, and to the interruption of chains
      of transmission to others not receiving PrEP. The rapid and large-scale roll-out of PrEP is a
      critical component of working towards the virtual elimination of HIV transmission by 2020.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study is proposed as implementation research to mimic the conditions that will occur when PrEP is rolled out at the population level. However, as the version of TDF/FTC used in this study, manufactured by Mylan, is not approved for use as PrEP in Australia, the study is conducted under the Clinical Trial Notification (CTN) scheme and within the CTN framework. After collection of consent and enrolment information, all follow-up information will be collected through electronic data capture to allow accurate and timely analyses.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HIV infection per 100 person years among study participants</measure>
    <time_frame>24 weeks after the last participant completed their last follow-up visit (Month 18 visit)</time_frame>
    <description>Statistical analyses of risk of HIV seroconversion among individuals who were prescribed PrEP (as part of the study) will focus on estimating the risk of seroconversion per 100 person years after TDF/FTC prescription and the effect modifying role of non-adherence to the prescribed medication schedule.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of HIV diagnoses among gay and bisexual men notified to Western Australian Department of Health</measure>
    <time_frame>number of HIV diagnoses in the 12 month period prior to the date of first recruitment will be compared to the annual number of HIV diagnoses in the 12 month period after the study is fully recruited</time_frame>
    <description>Number of diagnoses will be measured using routinely reported data from the Western Australia registry of HIV diagnoses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trends in test positivity of Sexually Transmitted Infections (STIs, gonorrhoea, chlamydia and infectious syphilis) among study participants</measure>
    <time_frame>24 weeks after the last participant completed their last follow-up visit (Month 18 visit)</time_frame>
    <description>To calculate trends in test positivity of STI (gonorrhoea, chlamydia and infectious syphilis) among study participants, and describe changes over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of enrollment to the study by clinic type</measure>
    <time_frame>up to 6 months</time_frame>
    <description>To measure in the four study sites</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>HIV Prevention</condition>
  <arm_group>
    <arm_group_label>TDF/FTC (300mg/200mg) once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)</intervention_name>
    <description>One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.</description>
    <arm_group_label>TDF/FTC (300mg/200mg) once daily</arm_group_label>
    <other_name>TDF/FTC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV negative at enrolment, with a negative HIV test result conducted at the enrolment
             clinic within seven days of initiating PrEP

          2. At high and ongoing risk for acquiring HIV infection [as defined by Behavioural
             Eligibility criteria in the Australasian Society for HIV, Viral Hepatitis and Sexual
             Health Medicine (ASHM) HIV PrEP Clinical Guidelines]

          3. Aged 18 years or over

          4. Live in WA or visit WA enough to attend clinics for follow-up assessments

          5. Willing and able to provide informed consent

          6. Medicare ineligible individuals may be enrolled if the clinical service is able to
             cover the costs of monitoring of the patient

        Exclusion Criteria:

          1. HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive
             status is not confirmed by testing, delay starting PrEP for at least one month and
             reconfirm negative HIV-1 status)

          2. Having an estimated creatinine clearance (glomerular filtration rate [eGFR]) &lt;60ml/min

          3. Having or developing clinical symptoms suggestive of lactic acidosis or pronounced
             hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort,
             and weakness)

          4. Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal
             anti-inflammatory drugs / NSAIDs)

          5. Allergic to TDF and/or FTC (based on self-report or recorded)

          6. Concurrently taking prescribed products containing FTC or TDF including ATRIPLA速,
             COMPLERA速, EMTRIVA, STRIBILD速, VIREAD, TAF (tenofovir alafenamide), GENVOYA, DESCOVY;
             other drugs containing lamivudine; HEPSERA

          7. Factors or conditions that may compromise a participant's access to health services
             for follow-up (incarceration or planned relocation and potential absence from Western
             Australia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cooper, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The Kirby Institute, UNSW Sydney</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Grulich, MBBS, MSc (Epid), PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Kirby Institute, UNSW Sydney</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Yeung, BHSc, MPH</last_name>
    <phone>+612 9385 0879</phone>
    <email>byeung@kirby.unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>South Terrace Sexual Health Clinic</name>
      <address>
        <city>Fremantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lewis Marshall, MBBS, MPH, FAFPHM, FAChSHM</last_name>
      <phone>+618 9431 2149</phone>
      <email>Lewis.Marshall@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Lewis Marshall, MBBS, MPH, FAFPHM, FAChSHM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GP on Beaufort</name>
      <address>
        <city>Mount Lawley</city>
        <state>Western Australia</state>
        <zip>6050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Goran Pervan, MBBS, FRACGP</last_name>
      <phone>+618 9262 8600</phone>
      <email>goran@gponbeaufort.com.au</email>
    </contact>
    <investigator>
      <last_name>Goran Pervan, MBBS, FRACGP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital Sexual Health Clinic</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Dykstra, MBChB, FAChSHM</last_name>
      <phone>+618 9224 2178</phone>
      <email>Christine.Dykstra@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Christine Dykstra, MBChB, FAChSHM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M Clinic</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justin Manuel</last_name>
      <phone>+618 9328 9720</phone>
      <email>Jmanuel@waaids.com</email>
    </contact>
    <investigator>
      <last_name>Haipeng Wang, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>October 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>October 29, 2017</last_update_submitted>
  <last_update_submitted_qc>October 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV prevention</keyword>
  <keyword>PrEP</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

